[ad_1]
Jakarta, CNBC Indonesia – The state pharmaceutical company Bio Farma revealed that the corona vaccine Sinovac has a 97% efficacy rate against Covid-19.
“Our clinical trial team found that preliminary data showed an efficacy of up to 97%,” said Iwan Setiawan, spokesperson for Bio Farma, as quoted by Reuters on Tuesday (8/12/2020).
Unfortunately, Iwan Setiawan did not specify whether this data came from the end-stage clinical trials, but later revealed that Bio Farma is still collecting data on the efficacy of the vaccines from the ongoing phase three clinical trials.
Previously, Sinovac revealed that its CoronaVac vaccine has a 97% efficacy rate against Covid-19 infection in healthy adults who received lower doses in phase 1 and phase 2 clinical trials.
A Sinovac spokesperson said that as of today, the company has not received an efficacy reading of its Phase 3 clinical trials. The Brazilian Butantan Institute is expected to release data on its end-stage clinical trials in Brazil on 15 May. December 2020.
Information alone, on Sunday night (6/12/2020), up to 1.2 million doses of the Sinovac vaccine arrived in Indonesia. This vaccine is now at Bio Farma’s head office in Bandung. The Sinovac vaccine is still awaiting an emergency use permit from the BPOM and a halal label from the Ulema Council of Indonesia (MUI).
NEXT PAGE >> Bio Farma produces 36 million doses of Sinovac vaccine next year
